Predniso(lo)ne

DRUG2 trials

Sponsors

Amgen, Medical University Innsbruck

Conditions

Minimal Change Disease (MCD)Primary Immune Thrombocytopenia

Phase 2

A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)

RecruitingNCT07710157

Medical University InnsbruckMinimal Change Disease (MCD)

Start: 2026-07-13End: 2029-06-30Target: 48Updated: 2026-08-17

Phase 3

A Study of Romiplostim Plus Predniso(lo)ne vs. Predniso(lo)ne Alone for the Treatment of Previously Untreated Primary Immune Thrombocytopenia (ITP)

RecruitingNCT07700238

AmgenPrimary Immune Thrombocytopenia

Start: 2026-08-21End: 2029-10-14Target: 126Updated: 2026-09-17